Perspective Therapeutics investor call on VMT-α-NET data at ESMO Congress 2026 - PERSPECTIVE THERAPEUTICS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed as the company is in a clinical development phase focused on drug therapy rather than commercial sales.
• The company has treated over 150 patients globally across its clinical trials, indicating significant capital deployment in clinical operations to date.

Guidance and Future Outlook:

• Management intends to initiate a Phase 3 registrational trial by leveraging data from Cohort 2 (20 millicuries) while potentially planning a protocol amendment to escalate to the 24-millicuries dose (Cohort 3) pending further data.
• An End-of-Phase 2 (EOP2) meeting with the FDA is targeted for the end of the current year to align on pivotal study design, eligibility criteria, and dosing.
• A follow-up oral presentation is scheduled for the North American Neuroendocrine Tumor Society (NANETS) conference.
• Long-term goal is to achieve approval based on disease control (Progression-Free Survival) with a strong safety profile, targeting patients progressing after somatostatin analogs.

Business Segments and Product Lines:

• VMT AlphaNet: The core asset is a lead-212 targeted alpha therapy for Gastroenteropancreatic Neuroendocrine Tumors (GAP-NETs).
  • Efficacy Data: 72% landmark Progression-Free Survival (PFS) at 18 months across all three cohorts; Overall Response Rate (ORR) of 37% in all SSTR2-positive patients (Cohort 2) and 47% in the 24-millicuries cohort (Cohort 3).
  • Safety Profile: Zero Grade 4 or 5 adverse events; no dose-limiting toxicities; no dysphagia; favorable renal safety with no significant long-term renal toxicity observed.
  • Dosing: Cohort 2 utilized 20 millicuries (4 doses); Cohort 3 utilized 24 millicuries.
• Pipeline: VMT01 (Lap and melanotide) is in dose escalation; active programs targeting FAP and CCQ2R are in development.

Market and Competitive Landscape:

• Target Population: Approximately 250,000 patients with neuroendocrine tumors in the US; ~12,000 new diagnoses annually, with 90% expressing SSTR2.
• Competitive Set: Current standard of care includes Somatostatin Analogs, Lutathera (beta-emitter, 13% ORR), and small molecules (Sunitinib, Cabozantinib, Everolimus).
• Differentiation: Alpha-particle therapy (Lead-212) offers a "hard, fast punch" capable of killing cancer cells with single particle hits vs. thousands required for beta-emitters, potentially offering deeper and more durable responses.
• Pivotal Study Design: Plans to compare against a "Treating Physician's Choice" arm, reflecting current market practice where patients may receive Lutathera, small molecules, or chemotherapy depending on physician preference.

Risks and Challenges:

• Patient Selection: Heterogeneous SSTR2 expression may lead to early progression in non-target lesions; registrational trials will likely require strict inclusion criteria (all lesions SSTR2 positive).
• Safety Monitoring: While current safety is favorable, ongoing monitoring is required for potential delayed hematologic toxicities (similar to risks seen with Lutathera, though none observed to date) and acute kidney injury (AKI).
• Data Maturity: Some response data is unconfirmed and PFS curves are based on immature data from early-phase trials; continued follow-up is needed to validate durability.
• Regulatory Uncertainty: Final approval path and comparator arms remain subject to FDA discussions and regulatory negotiations.

Management Commentary and Tone:

• Tone: Highly confident and enthusiastic; management described the data as "extraordinary" and "category-defining."
• Key Message: Emphasis on the unique mechanism of the "net zero charge" proprietary chelator which minimizes off-target toxicity and maximizes the therapeutic window.
• Clinical Sentiment: Management reported strong enthusiasm from clinicians and patients, noting high enrollment interest due to the unmet medical need for durable disease control.

Analyst Questions and Answers:

• Regulatory Endpoints: FDA is expected to prioritize PFS (disease control) as the primary endpoint, though ORR could support accelerated approval or breakthrough designation.
• Dose Selection: Management favors the 20-millicuries dose for the initial Phase 3 launch due to robust benefit-risk data and follow-up, with a potential automatic escalation to 24-millicuries in the protocol.
• Safety Clarifications: Two Grade 3 AKI events were reported (one from Cohort 1, one from Cohort 2); both were attributed to disease progression (ureteral obstruction) or patient comorbidities rather than the drug itself, with no chronic renal issues observed.
• Response Kinetics: Responses may appear later than with beta-emitters due to the "slow dying" nature of neuroendocrine tumors; the alpha mechanism causes double-strand DNA breaks, but tumor shrinkage on CT scans may lag behind cellular death.
• Comparators: No direct cross-trial comparison to NETA 1 or Lutathera was deemed appropriate due to differing patient populations and study maturity; management aims to prove superiority over "Treating Physician's Choice" in a Phase 3 setting.
• Exclusion Criteria: Management estimates that 60-75% of treated patients in early cohorts would meet strict Phase 3 inclusion criteria (homogeneous SSTR2 expression).

Other Key Points:

• Mechanism of Action: The proprietary chelator ensures <5% leakage of Bismuth-212 (compared to up to 30% with other chelators), reducing off-target radiation exposure.
• Toxicity Profile: The most common side effect is reversible, mild alopecia; nausea was reported but did not impact treatment adherence.
• Renal Safety: No significant myelosuppression or clinically significant renal toxicity was observed; the net-neutral charge design is credited for this favorable profile.
• Study Continuation: Cohort 4 is enrolling (a variant of the 20-millicuries dose) but no data is yet available.